Cost-Effectiveness Analysis of Using Everolimus or Axitinib in Patients with Metastatic Renal Cell Carcinoma WHO Have Failed to Use of Pazopanib or Sunitinib in First-Line Treatment
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.2223
https://www.valueinhealthjournal.com/article/S1098-3015(16)33589-6/fulltext
Title :
Cost-Effectiveness Analysis of Using Everolimus or Axitinib in Patients with Metastatic Renal Cell Carcinoma WHO Have Failed to Use of Pazopanib or Sunitinib in First-Line Treatment
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33589-6&doi=10.1016/j.jval.2016.09.2223
First page :
A735
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2109